Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
173
resultados
Última actualización
23/06/2025 [12:49:00]
Resultados 75 a 100 de 173
Resumen de: US2025160749A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: US2025160748A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: US2025160703A1
A system for reducing sensor variability includes a sensor configured to generate real-time data relating to glucose sensitivity. The system causes performance of accessing the real-time data from the sensor relating to glucose sensitivity and inputting the real-time data into a machine learning model. The system also causes performance of estimating by the machine learning model an expected glucose sensitivity based on the real-time data and correcting the glucose sensitivity based on the expected glucose sensitivity.
Resumen de: US2025160695A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160692A1
Polyesteramide (PEA) copolymers are disclosed, having structures that include repeating units that contain various monomer residues characterized herein and present in the repeating units at defined ranges of molar equivalents. These copolymers can possess a number of important advantages for providing longer performing glucose sensors and/or for simplifying their design. For example, in vivo modeling has confirmed that these polymers exhibit both decreased collagen deposition and increased neovascularization (angiogenesis). Additional testing has demonstrated favorable oxygen and glucose transport capabilities, as well as other relevant properties.
Resumen de: US2025160694A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160697A1
Certain aspects of the present disclosure relate to a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Resumen de: US2025160696A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160642A1
In some example embodiments, there is provided a method, which includes sending a message to a server, wherein the message includes a request for a share code to enable another user to access, via a first computer, analyte data obtained from a host-patient associated with a receiver and/or an analyte report for the host-patient associated with the receiver; receiving, in response to the sending, the share code generated by the server, wherein the share code comprises a checksum portion, a password portion, and an identifier portion indicative of the host-patient; generating a user interface view including the share code; and displaying the user interface view including the share code, wherein the share code enables the other user to access, via the first computer, the analyte data and/or the analyte report. Related systems, methods, and articles of manufacture are also disclosed.
Resumen de: US2025161567A1
Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025161568A1
Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025161566A1
Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025166855A1
Presented herein is a handheld analyte measurement device. The analyte measurement device includes one or more software applications to help the user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with the handheld analyte measurement device.
Resumen de: US2025166814A1
Medical devices, systems, and methods related thereto a glucose monitoring system having a first display unit in data communication with a skin-mounted assembly, the skin-mounted assembly including an in vivo sensor and a transmitter. The first display unit and a second display unit are in data communication with a data management system. The first display unit comprises memory that grants a first user first access level rights and the second display unit comprises memory that grants a second individual second access level rights.
Resumen de: US2025166780A1
Systems and methods are disclosed that employ several or numerous factors in the determination of a glycemic urgency index (GUI), which may be based on a measured blood glucose level as well as other factors. The other factors may include time derivatives of the glucose level and/or other factors, e.g., user-entered data, data measured by other sensors or received from a network source, or historical data. The GUI is then presented to the user in an interesting way, e.g., via a background color or other inconspicuous notifier, e.g., on a mobile device such as a smart phone. The GUI may also be employed in the triggering of actionable alerts and alarms on an electronic device for the user. The GUI, or another index calculated from combinations of the variables and parameters described, may further be employed to drive a medicament delivery device such as a pump.
Resumen de: WO2024012479A1
Devices, systems and methods for blood glucose monitoring. The device includes a light emitter, configured to emit light signals; a light receiver, configured to receive the reflected light signal; a controller, configured to operatively connect with the light emitter and the light receiver; and an enclosure. The light signal comprises a first light signal having a first wavelength of about 940nm, a second light signal having a second wavelength of about 1350nm, and/or a third light signal having a third wavelength of about 1500nm, wherein the controller comprises an operating module, and further comprises or operatively connects with a data processing system comprising a machine learning module that analyzes the data signal to generate an output data. The devices, systems and methods are non-invasive and monitor blood glucose levels in real time with high accuracy.
Resumen de: EP4555927A1
Techniques disclosed herein relate to glucose level measurement and/or management. In some embodiments, the techniques involve obtaining in vivo characteristics of a glucose sensor predicted using fabrication process measurement data associated with the glucose sensor, the in vivo characteristics including an in vivo sensitivity, an in vivo intercept, or a combination thereof; receiving sensor measurement data measured by the glucose sensor, the sensor measurement data including sensor current (Isig), counter voltage (Vcntr), electrochemical impedance spectroscopy (EIS) data, an age of the glucose sensor, or a combination thereof; and estimating a sensor glucose (SG) value using an SG model, wherein input parameters of the SG model include the in vivo characteristics of the glucose sensor and the sensor measurement data, and the SG value is an output of the SG model.
Resumen de: EP4557303A1
Disclosed herein are techniques related to determining medical parameters. In some embodiments, the techniques involve: obtaining a metric of insulin dosage for a patient; and determining at least one carbohydrate-to-insulin ratio for the patient based at least in part on a model and using the obtained metric of insulin dosage for the patient, wherein parameters of the model were determined based on data associated with a population of patients.
Resumen de: EP4555928A1
A system for reducing sensor variability includes a sensor configured to generate real-time data relating to glucose sensitivity. The system causes performance of accessing the real-time data from the sensor relating to glucose sensitivity and inputting the real-time data into a machine learning model. The system also causes performance of estimating by the machine learning model an expected glucose sensitivity based on the real-time data and correcting the glucose sensitivity based on the expected glucose sensitivity.
Resumen de: US2025152808A1
A device for delivering medicament to a user, the device configured to be mounted to the user, the device including a baseplate comprising: a first opening and second opening to align with a first port and second port of a micropump, respectively; a first fluid channel in fluid communication with the second opening of the baseplate; and a platform for receiving a pressure sensor, the platform having an opening that communicates with the first fluid channel to enable the pressure sensor to sense pressure in the fluid channel.
Resumen de: AU2023373672A1
Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.
Resumen de: US2025152816A1
Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025152817A1
Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.
Resumen de: US2025152673A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Nº publicación: US2025152814A1 15/05/2025
Solicitante:
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc
Resumen de: US2025152814A1
Techniques for therapy delivery for diabetes treatment are provided. In some embodiments, the techniques may involve identifying an object as a food item based on a representation of the object. In some embodiments, the techniques may involve generating nutrition information or volume information of the food item. The techniques may involve determining that the nutrition information or the volume information of the food item exceeds a threshold. The techniques may involve determining that the patient's glucose level will rise based on the determination the nutrition information or the volume information of the particular food item exceeds the threshold. The techniques may involve generating therapy information for a patient based on the determination that the patient's glucose level will rise. The techniques may involve automatically administering insulin to the patient to cause the glucose level of the patient to lower to within a predetermined range and based on the therapy information.
BOPI
Sede Electrónica
